Rita Nanda to Combined Modality Therapy
This is a "connection" page, showing publications Rita Nanda has written about Combined Modality Therapy.
Connection Strength
0.159
-
Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2024 Apr 15; 130(8):1210-1220.
Score: 0.045
-
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
Score: 0.038
-
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res. 2017 Aug 01; 23(15):4066-4076.
Score: 0.028
-
Treatment of leptomeningeal carcinomatosis: current challenges and future opportunities. J Clin Neurosci. 2015 Apr; 22(4):632-7.
Score: 0.024
-
Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017. Ann Surg Oncol. 2015 Jan; 22(1):75-81.
Score: 0.023